Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Acetyl-L-leucine for Niemann-Pick type C – a multi-national, rater-blinded phase II trial

View ORCID ProfileTatiana Bremova-Ertl, View ORCID ProfileJen Claassen, Tomas Foltan, Jordi Gascón Bayarri, View ORCID ProfilePaul Gissen, Andreas Hahn, View ORCID ProfileAnhar Hassan, Anita Hennig, Simon Jones, View ORCID ProfileMiriam Kolniková, View ORCID ProfileKyriakos Martakis, View ORCID ProfileUma Ramaswami, Reena Sharma, Susanne Schneider
doi: https://doi.org/10.1101/2020.12.22.20248704
Tatiana Bremova-Ertl
1Department of Neurology, University Hospital Bern (Inselspital) and University of Bern, Bern, Switzerland ; Center for Rare Diseases, University Hospital Bern (Inselspital) and University of Bern, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tatiana Bremova-Ertl
  • For correspondence: bremova@gmail.com
Jen Claassen
2Department of Neurology, Essen University Hospital, University of Duisburg-Essen, Essen, German; Department of Neurocritical Care, Neurological and Neurosurgical First Stage Rehabilitation and Weaning, MediClin Klinik Reichshof, Berglandstr.1, 51580, Reichshof-Eckenhagen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jen Claassen
Tomas Foltan
3Department of Pediatric Neurology, Comenius University in Bratislva, Faculty of Medicine, National Institute of Children’s Diseases, Limbova 1, 83340 Bratislava, Slovak Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jordi Gascón Bayarri
4Department of Neurologic Diseases and Neurogenetics, Institut d’Investigació Biomèdica de Bellvitge, Avinguda de la Granvia de l’Hospitalet, 199, 08908 L’Hospitalet de Llobregat, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Gissen
5NIHR Great Ormond Street Hospital Biomedical Research Centre, University College London, London WC1N 1EH, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paul Gissen
Andreas Hahn
6Department of Child Neurology, Justus Liebig University, Giessen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anhar Hassan
7Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anhar Hassan
Anita Hennig
8Department of Neurology and German Center for Vertigo and Balance Disorders, University Hospital, Ludwig Maximilians University, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon Jones
9Willink Unit, Manchester Centre for Genomic Medicine, Royal Manchester Children’s Hospital, Manchester, M13 9WL, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miriam Kolniková
3Department of Pediatric Neurology, Comenius University in Bratislva, Faculty of Medicine, National Institute of Children’s Diseases, Limbova 1, 83340 Bratislava, Slovak Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Miriam Kolniková
Kyriakos Martakis
6Department of Child Neurology, Justus Liebig University, Giessen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kyriakos Martakis
Uma Ramaswami
10Lysosomal Storage Disorder Unit, Royal Free London NHS Foundation Trust, Pond Street, Londonm, NW3 2QG, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Uma Ramaswami
Reena Sharma
11Department of Adult Metabolic Medicine, Salford Royal Foundation NHS Trust, Ladywell NW2, Salford, M6 8HD, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susanne Schneider
8Department of Neurology and German Center for Vertigo and Balance Disorders, University Hospital, Ludwig Maximilians University, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Niemann-Pick disease type C (NPC) is a rare autosomal recessive neurodegenerative disorder characterized by symptoms such as progressive cerebellar ataxia and cognitive decline. The modified amino acid N-acetyl-leucine has been associated with positive symptomatic and neuroprotective, disease-modifying effects in observational case studies and animal and cellular models of NPC. Therefore, the effects of the active L-enantiomer, N-acetyl-L-leucine (NALL, Sponsor Code IB1001) were evaluated in paediatric and adult patients with NPC.

Methods We conducted a 9-center, multinational, open-label, rater-blinded Phase 2 study to assess the safety and efficacy of NALL for the treatment of pediatric (≥ 6 years) and adult patients with NPC (IB1001-201 clinical trial). Eligible patients were assessed during three study phases: a baseline period (with or without a study run-in), a 6-week treatment period (dosage of NALL 4 g/d in patients aged ≥13 years; weight tiered doses for patients aged 6-12 years based on approximately 0.1 g/kg/day), and a 6-week post-treatment washout period. The primary outcome was based on the Clinical Impression of Change in Severity (CI-CS) assessment (assessed on a 7-point Likert scale) performed by blinded, centralized raters who compared videos of patients performing a pre-defined primary anchor test (either the 8-Meter Walk Test (8MWT) or 9-Hole Peg Test of the Dominant Hand (9HPT-D)) at different study periods. Secondary outcomes included the cerebellar function evaluations, namely the Scale for Assessment and Rating of Ataxia (SARA), the Spinocerebellar Ataxia Functional Index (SCAFI), and the Clinical Global Impression Scales (CGI) as well as the EuroQol-5D/VAS.

Results Thirty-three subjects aged 7 to 64 years with a confirmed diagnosis of NPC were enrolled according to the trial protocol between 04 September 2019 and 30 January 2020. Thirty-two patients were included in the modified intention-to-treat analysis. IB1001 met its CI-CS primary endpoint (mean difference 0.86 ((90% CI 0.25,1.75, p=0.029). IB1001 also met secondary endpoints, including improvement during treatment on the SARA scale (mean difference −1.19 (90% CI −1.8, −0.5, p=0.001)), investigator’s CGI-C assessment (mean difference from baseline to the end of treatment 0.6 (90% CI 0.5, 1.0, p<0.001)), clinically worsening over the washout period on the SARA (mean difference 1.45 (90% CI 0.5, 2.0, p=0.002)) and investigator’s CGI-C assessment (washout mean difference −0.5 (90% CI −1.0, 0.0, p=0.006). IB1001 was well-tolerated with no treatment related serious adverse reactions occurring.

Conclusions Consistent with its pharmacological action, IB1001 rapidly improved symptoms, functioning, and quality of life in 6-weeks, the clinical effect of which was lost after the 6-week, post-treatment washout period. High consistency and statistical significance between the primary and secondary endpoints demonstrate a clear, clinically meaningful improvement with IB1001. IB1001 was well-tolerated and no drug-related serious adverse events were reported, demonstrating a favorable risk/benefit profile for the treatment of NPC (Funded by IntraBio; ClinicalTrials.gov number, NCT03759639; EudraCT number 2018-004331-71).

Competing Interest Statement

Competing interest: All authors have completed the ICMJE uniform disclosure form and declare: no support from any organisation for the submitted work; SS was supported by the Munich Clinician Scientist Programme, the Ara Parseghian Medical Research and the Verum Stiftung. TBE received honoraria for lecturing from Actelion and Sanofi Genzyme. AH Hassan has received previous support from AbbVie and NCATS, and serves on the Editorial Board of Parkinsonism and Related Disorders. UR has received research grants from Amicus and Takeda, advisory board and lecture fee from Amicus, Chiesi, Genzyme; no other relationships or activities that could appear to have influenced the submitted work.

Clinical Trial

ClinicalTrials.gov number, NCT03759639; EudraCT number 2018-004331-71

Clinical Protocols

https://www.medrxiv.org/content/10.1101/2020.03.11.20034256v1

Funding Statement

The trial was sponsored and funded by IntraBio Ltd. A confidential agreement was executed with each Participating Organisation (i.e. trial site)/ its respective principal investigator in accordance with ICH GCP and applicable national clinical trial compensation guidelines which detailed how the Sponsor shall provide financial remuneration for the performance of the Clinical Trial to the Participating Organisation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The studies have been approved by the responsible central research ethics committees and institutional review boards, including the Ethics Committee of Ludwig Maximilian University of Munich (19135), National Institute of Child Diseases Bratislava Ethics Committee (EudraCT 201800443171), Bellvitge Hospital University Clinical Research Ethics Committee (AC00119); East Midlands, Derby Research Ethics Committee (259038); Mayo Clinic Institutional Review Board (18011974).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The datasets generated during and/or analysed during the current study are available from IntraBio Ltd. Due to confidentiality agreements with research collaborators, the data are not publicly available but are available from the corresponding author and with permission from IntraBio Ltd on reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 26, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Acetyl-L-leucine for Niemann-Pick type C – a multi-national, rater-blinded phase II trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Acetyl-L-leucine for Niemann-Pick type C – a multi-national, rater-blinded phase II trial
Tatiana Bremova-Ertl, Jen Claassen, Tomas Foltan, Jordi Gascón Bayarri, Paul Gissen, Andreas Hahn, Anhar Hassan, Anita Hennig, Simon Jones, Miriam Kolniková, Kyriakos Martakis, Uma Ramaswami, Reena Sharma, Susanne Schneider
medRxiv 2020.12.22.20248704; doi: https://doi.org/10.1101/2020.12.22.20248704
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Acetyl-L-leucine for Niemann-Pick type C – a multi-national, rater-blinded phase II trial
Tatiana Bremova-Ertl, Jen Claassen, Tomas Foltan, Jordi Gascón Bayarri, Paul Gissen, Andreas Hahn, Anhar Hassan, Anita Hennig, Simon Jones, Miriam Kolniková, Kyriakos Martakis, Uma Ramaswami, Reena Sharma, Susanne Schneider
medRxiv 2020.12.22.20248704; doi: https://doi.org/10.1101/2020.12.22.20248704

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (51)
  • Cardiovascular Medicine (455)
  • Dentistry and Oral Medicine (83)
  • Dermatology (55)
  • Emergency Medicine (159)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (191)
  • Epidemiology (5297)
  • Forensic Medicine (3)
  • Gastroenterology (198)
  • Genetic and Genomic Medicine (760)
  • Geriatric Medicine (80)
  • Health Economics (214)
  • Health Informatics (702)
  • Health Policy (363)
  • Health Systems and Quality Improvement (224)
  • Hematology (100)
  • HIV/AIDS (165)
  • Infectious Diseases (except HIV/AIDS) (5938)
  • Intensive Care and Critical Care Medicine (368)
  • Medical Education (105)
  • Medical Ethics (25)
  • Nephrology (83)
  • Neurology (772)
  • Nursing (43)
  • Nutrition (135)
  • Obstetrics and Gynecology (146)
  • Occupational and Environmental Health (234)
  • Oncology (481)
  • Ophthalmology (153)
  • Orthopedics (39)
  • Otolaryngology (97)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (141)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (138)
  • Primary Care Research (99)
  • Psychiatry and Clinical Psychology (865)
  • Public and Global Health (2035)
  • Radiology and Imaging (354)
  • Rehabilitation Medicine and Physical Therapy (159)
  • Respiratory Medicine (287)
  • Rheumatology (94)
  • Sexual and Reproductive Health (74)
  • Sports Medicine (77)
  • Surgery (110)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)